NEW YORK, Jan. 27 (GenomeWeb News) - Sirna Therapeutics and Eli Lilly plan to develop RNAi therapeutics for cancer, the companies said today.
During the eighteen-month collaboration, the companies will test Sirna's small interfering RNAs against oncology targets from Lilly.
According to Sirna, based in Boulder, Colo., this is its first collaboration with a large pharmaceutical company.